Physically Cross-Linked DNA Hydrogel-Based Sustained Cytokine Delivery for In Situ Diabetic Alveolar Bone Rebuilding

Wei Li, Chengshi Wang, Zhenghao Wang, Liping Gou, Ye Zhou, Ge Peng, Min Zhu, Jiayi Zhang, Ruoqing Li, Hengfan Ni, Lei Wu, Wanli Zhang, Jiaye Liu, Yali Tian, Zhong Chen, Yuan-Ping Han, Nanwei Tong, Xianghui Fu, Xiaofeng Zheng, Per-Olof Berggren

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)


The development of a biodegradable and shape-adaptable bioscaffold that can enhance local cytokine retention and bioactivity is essential for the application of immunotherapy in periodontal diseases. Here, we report a biodegradable, anti-inflammatory, and osteogenic ILGel that uses a physically cross-linked DNA hydrogel as a soft bioscaffold for the long-term sustained release of cytokine interleukin-10 (IL-10) to accelerate diabetic alveolar bone rebuilding. Porous microstructures of ILGel favored the encapsulation of IL-10 and maintained IL-10 bioactivity for at least 7 days. ILGel can be gradually degraded or hydrolyzed under physiological conditions, avoiding the potential undesired side effects on dental tissues. Long-term sustained release of bioactive IL-10 from ILGel not only promoted M2 macrophage polarization and attenuated periodontal inflammation but also triggered osteogenesis of mesenchymal stem cells (MSCs), leading to accelerated alveolar bone formation and healing of alveolar bone defects under diabetic conditions in vivo. ILGel treatment significantly accelerated the defect healing rate of diabetic alveolar injury up to 93.42 ± 4.6% on day 21 post treatment compared to that of free IL-10 treatment (63.30 ± 7.39%), with improved trabecular architectures. Our findings imply the potential application of the DNA hydrogel as the bioscaffold for cytokine-based immunotherapy in diabetic alveolar bone injury and other periodontal diseases.

Original languageEnglish
Pages (from-to)25173-25182
Number of pages10
JournalACS Applied Materials & Interfaces
Issue number22
Early online date31 May 2022
Publication statusPublished (in print/issue) - 8 Jun 2022

Bibliographical note

Funding Information:
This study was supported by the National Natural Science Foundation of China (81801589, 82070846), the Center of Excellence-International Collaboration Initiative Grant of West China Hospital (139180012), the Program for Overseas High-Level Talents Introduction of Sichuan Province of China (21RCYJ0046), the China Postdoctoral Science Foundation (2018M643487, 2021TQ0225, 2021M702370), the Post-Doctor Research Project, West China Hospital of Sichuan University (2021HXBH065, 2019HXBH027), a Grant from Technology Innovation R & D Project of Chengdu Science and Technology Bureau (2019-YF05-01243-SN), and the 1.3.5 project for disciplines of excellence, West China Hospital of Sichuan University (ZYGD18017).

Publisher Copyright:
© 2022 American Chemical Society. All rights reserved.


  • Bone Regeneration
  • Cytokines
  • DNA
  • Delayed-Action Preparations
  • Diabetes Mellitus
  • Humans
  • Hydrogels/chemistry
  • Interleukin-10
  • Osteogenesis/genetics
  • Periodontal Diseases


Dive into the research topics of 'Physically Cross-Linked DNA Hydrogel-Based Sustained Cytokine Delivery for In Situ Diabetic Alveolar Bone Rebuilding'. Together they form a unique fingerprint.

Cite this